Gapping up
In reaction to earnings/guidance:
- HIMX +7.1%, SMPL +2%, SGH +1.8%, UMC +1.5%
Other news:
- CAHC +9.4% (LumiraDx to list on Nasdaq via merger with CA Healthcare Acquisition Corp)
- NVST +8.9% (to join S&P MidCap 400)
- AKBA +7.8% (FGEN's news is seen as a positive for AKBA's competing anemia drug candidate)
- TMDX +6.9% (receives positive FDA Advisory Committee vote for OCS Heart System)
- APDN +6.9% (enters into a Material Transfer Agreement that establishes a real-time surveillance program for the tracking of SARS-CoV-2 mutations in Northwell's COVID-positive specimens)
- IDCC +6% (to join S&P SmallCap 600)
- EBON +5.2% (responds to Hindenburg Report)
- ALKS +5.2% (entered into a clinical trial collaboration and supply agreement with Merck (MRK) for a planned phase 3 study to evaluate nemvaleukin alfa in combination with KEYTRUDA in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer)
- NCLH +3.5% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg)
- CCL +3% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg)
- AER +2.5% (announced its major business transactions during the first quarter 2021)
- RCL +2.3% (US cruises could resume by mid-summer with restrictions, says CDC, according to Bloomberg)
- FOXA +2.1% (files suit against Flutter to enforce its rights to acquire interest in FanDuel)
- SAIC +1.9% (awarded a contract worth ~$800 mln from US Army)
- QGEN +1.3% (launches QIAseq DIRECT SARS-CoV-2 Kit)
Analyst comments:
- KTB +2.8% (upgraded to Buy from Neutral at UBS)
- ANF +2.4% (upgraded to Buy from Neutral at UBS)
- LB +2.4% (upgraded to Buy from Neutral at UBS)
- VIAC +2% (upgraded to Outperform from Peer Perform at Wolfe Research)
- EPR +1.6% (upgraded to Buy from Underperform at BofA Securities)